No data to show
XSTO
LIPUM
Market cap33mUSD
Jun 27, Last price
15.00SEK
1D
2.39%
1Q
0.67%
IPO
-40.00%
Name
Lipum AB (publ)
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
35.20%
Rev. gr., 5y
-20.63%
Revenues
0k
-100.00%
Net income
-56m
L+49.32%
CFO
-87m
L+139.53%
Profile
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 53 | |||||||
Cost of revenue | 26,001 | 61,432 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (25,948) | (61,432) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 160 | |||||||
Tax Rate | ||||||||
NOPAT | (25,948) | (61,592) | ||||||
Net income | (55,516) 49.32% | (37,178) -2.79% | (38,245) -27.02% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 79,715 | 15,276 | 39,161 | |||||
BB yield | -31.04% | -28.07% | -44.19% | |||||
| Debt | ||||||||
Debt current | 10,000 | |||||||
Long-term debt | 1,868 | 1,761 | 1,661 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | (1,661) | |||||||
Net debt | 5,236 | (8,465) | (31,176) | |||||
| Cash flow | ||||||||
Cash from operating activities | (86,534) | (36,126) | (52,406) | |||||
CAPEX | (188) | (60) | ||||||
Cash from investing activities | (188) | (60) | ||||||
Cash from financing activities | 82,915 | 13,703 | 38,250 | |||||
FCF | (27,104) | (26,096) | (61,641) | |||||
| Balance | ||||||||
Cash | 6,632 | 10,226 | 32,837 | |||||
Long term investments | ||||||||
Excess cash | 6,632 | 10,223 | 32,837 | |||||
Stockholders' equity | (213,743) | (161,201) | (124,438) | |||||
Invested Capital | 247,607 | 167,534 | 153,650 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 21,400 | 8,346 | 6,353 | |||||
Price | 12.00 84.05% | 6.52 -53.26% | 13.95 -24.59% | |||||
Market cap | 256,795 371.91% | 54,416 -38.60% | 88,629 15.32% | |||||
EV | 262,031 | 45,951 | 57,453 | |||||
EBITDA | (25,908) | (61,421) | ||||||
EV/EBITDA | ||||||||
Interest | 534 | 169 | ||||||
Interest/NOPBT | ||||||||